---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-24-000036"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:24:52.194124+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance

## Summary
- Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.
- Net loss $6.6M ($0.19/share) vs $1.0M loss in Q2 2023; prior year had $2.7M sale-leaseback gain.
- Adjusted EBITDA loss $4.3M, up 166% from $1.6M loss in Q2 2023.
- FY2024 revenue guidance narrowed to $50.6-52.1M (from $49.7-52.9M); net loss guided $23.5-24.5M (improved).
- Stavros Vizirgianakis appointed Chairman effective May 7, 2024, succeeding retiring Andrew Makrides.

## SEC filing metadata
- accession: 0000719135-24-000036
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913524000036/0000719135-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913524000036/apyx-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-24-000036
- JSON: https://secwatch.observer/filing/0000719135-24-000036.json
- Plain text: https://secwatch.observer/filing/0000719135-24-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.